Truvada + estradiol

This drug combination refers to the co-administration of Truvada (a fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine) and estradiol, often accompanied by leuprolide acetate (Lupron) for testosterone suppression, as part of a gender-affirming hormone therapy (GAHT) regimen. It is primarily studied by Johns Hopkins University in Phase I clinical trials to evaluate the two-way pharmacokinetic and pharmacodynamic interactions in transgender women using Truvada for HIV pre-exposure prophylaxis (PrEP). Truvada acts by inhibiting HIV reverse transcriptase through its components tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor) and emtricitabine (a nucleoside reverse transcriptase inhibitor), while estradiol serves as exogenous estrogen for feminization. Research in this area aims to determine if estrogen-based hormone therapy reduces the protective concentrations of PrEP medications, as some studies have suggested a potential decrease in tenofovir levels in the presence of exogenous estrogens.

Brand names

Lupron

Other names

tenofovir disoproxil fumarate + emtricitabine + estradiolTDF/FTC + estradiolPrEP-GAHT Interactions in TGW